NCT04745767View on ClinicalTrials.gov

A Study of Different Forms of TAK-994 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

March 25, 2021

Study Completion Date

April 5, 2021

Conditions
Healthy Participants
Interventions
DRUG

TAK-994

T2 formulation.

DRUG

TAK-994

T1 formulation.

DRUG

TAK-994

T3 formulation.

DRUG

TAK-994

T4 formulation.

DRUG

TAK-994

T5 formulation.

Trial Locations (2)

68502

Celerion Lincoln, NE site, Lincoln

85283

Celerion Tempe, AZ site, Tempe

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04745767 - A Study of Different Forms of TAK-994 in Healthy Adults | Biotech Hunter | Biotech Hunter